Marc S. Ernstoff, MD, chief for the ImmunoOncology branch of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis at the National Cancer Institute, discusses why physicians would treat metastatic melanoma with immunotherapy prior to small molecule inhibitors in most cases.
2023
CHARACTERISTICS IN PATIENTS WITH SECOND PRIMARY MELANOMA LESIONS VS. SINGLE PRIMARY MELANOMA LESIONS
The following is a summary of “Survival and tumor characteristics of patients presenting with single primary versus second primary melanoma lesions,” published in the MAY 2023 issue of Dermatology by Sarver, et al.
Researchers Study Genetic Changes in Tumors of Recently Deceased Patients With Melanoma
Researchers have found that studying the landscape of DNA and RNA alterations across multiple organs of metastasis may provide a new direction in cancer therapeutics to address treatment failure, according to a new study published by Liu et al in Nature Medicine. The new findings from analyzing genetic changes in the organs of recently deceased patients may help researchers understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies.
Factors that Impact Treatment Selection for Melanoma
Sunandana Chandra, MD, MS: Let’s switch gears and talk about unresectable metastatic melanoma next. Dr Pavlick, when a patient walks in your office with unresectable metastatic melanoma, what are the decisions that drive your selection of treatments to offer or discuss with the patient?